3/20/2015 | PP | Oxigene plans to conduct $10 million registered offering of its units
|
5/23/2014 | PP | Oxigene raises $16 million in at-the-market direct offering of stock
|
2/12/2014 | PP | Oxigene prices $12 million public offering of units at $2.05 per unit
|
9/19/2013 | PP | Oxigene eyes $5.8 million private placement of convertible preferreds
|
8/29/2013 | PP | Oxigene reports it now plans to sell common shares in public offering
|
8/8/2013 | PP | Oxigene will price $20 million public offering of common-share units
|
4/11/2013 | PP | Oxigene plans $5 million private placement of convertible preferreds
|
9/5/2012 | PP | Oxigene plans to conduct $2.94 million at-the-market sale of shares
|
6/14/2012 | PP | Oxigene to raise $10 million via at-market issuance sales agreement
|
5/31/2012 | CVPF | Oxigene files $40 million shelf covering stock, preferreds and debt
|
11/28/2011 | PP | Oxigene secures $20 million through common stock purchase agreement
|
10/14/2011 | PP | Oxigene terminates its $40 million committed equity financing facility
|
7/8/2011 | PP | Oxigene to conduct a $3.1 million at-market issuance sales agreement
|
6/29/2011 | PP | Oxigene raises $15.18 million via at-market issuance sales agreement
|
3/11/2010 | PP | New Issue: Oxigene to pocket $7.5 million via private placement of common shares
|
3/11/2010 | PP | Market Commentary: Candax seeks C$13 million; Image Metrics pockets $8 million; Oxigene plans stock, warrant sale
|
7/15/2009 | PP | New Issue: Oxigene orchestrates $10 million direct offering of common share units
|
7/15/2009 | PP | Market Commentary: GTO aims for C$100 million; Oxigene plans direct offering; Manas wraps A$4 million equity deal
|
11/14/2008 | CVHY | Oxigene files $50 million shelf
|
10/2/2008 | PP | Market Commentary: Cosan plans $180 million private placement of shares; Oxigene completes $2.48 million PIPE sale
|
10/1/2008 | PP | New Issue: Oxigene secures $2.48 million from private placement of shares
|
2/22/2008 | PP | Market Commentary: Lumera obtains $25 million equity line; Elandia sells $40 million preferreds
|
2/21/2008 | PP | Market Commentary: Romarco opts for non-brokered sale; Sterling plans C$35 million deal; Nemi Northern prices notes
|
2/21/2008 | PP | New Issue: Oxigene releases further details on $40 million committed equity financing facility
|
2/20/2008 | PP | New Issue: Oxigene arranges $40 million committed equity financing facility
|
2/20/2008 | PP | Market Commentary: HSW snags $18.4 million investment; Mountain Lake plans sale; Oxigene gets $40 million financing deal
|
10/25/2006 | BT | Oxigene seeking most valuable path, partnership for CA4P
|
9/21/2006 | BT | Oxigene: Combination therapy suppresses tumor regrowth in animals
|
9/12/2006 | BT | Oxigene to focus on CA4P for macular degeneration
|
7/26/2006 | BT | Oxigene reports net loss of $4.9 million for second quarter
|
7/26/2006 | BT | Market Commentary: DOV comes off highs; Neurocrine extends losses after hours; bird flu stocks fly; NicOx rises
|
6/5/2006 | BT | Oxigene announces positive data from phase 2 trials of CA4P for thyroid cancer
|
5/15/2006 | BT | FDA grants orphan drug status to Oxigene's CA4P for treatment of ovarian cancer
|
5/5/2006 | BT | OxiGene gets patent for oncology product
|
4/26/2006 | BT | Oxigene reports first-quarter net loss of $3.3 million
|
3/29/2006 | BT | OxiGene to license newly patented novel small-molecule drug
|
3/23/2006 | BT | OxiGene completes enrollment in trial evaluating CA4P with chemotherapy
|
3/1/2006 | BT | Oxigene says net loss widens to $11.9 million in 2005
|
2/3/2006 | BT | Oxigene to evaluate CA4P for lung cancer
|
12/21/2005 | BT | Oxigene underwriters exercise greenshoe for 975,000 shares, raising offering to $27.3 million
|
12/15/2005 | BT | Market Commentary: OSI Pharma on deck; Oxigene off on steep discount; BioCryst slips on PIPE; Somaxon sinks on debut
|
12/15/2005 | BT | New Issue: Oxigene raises $23.7 million in upsized follow-on at $3.65, discounted from $4.30 close
|
12/14/2005 | BT | Market Commentary: BB Biotech deal on tap Friday; Amgen, Abgenix ink long-awaited merger; Oxigene seen on deck
|
12/12/2005 | BT | Oxigene given U.K. approval for phase 3 trial of Combretastatin A4P
|
12/7/2005 | BT | Market Commentary: Voyager IPO at bat; Amgen off; ViroPharma jumps after deal; Dendreon slides; Rigel up sharply
|
12/5/2005 | BT | OxiGENE starts trial that pairs CA4P vascular-disrupting compound with Genentech's Avastin
|
12/5/2005 | BT | Market Commentary: Noven soars on ADHD patch news; Ligand bounces on board expansion; Progenics off sharply
|
12/1/2005 | BT | Oxigene launches follow-on offering of 6 million shares via SG Cowen
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
11/16/2005 | BT | Oxigene says research indicates CA4P and Oxi4502 with Avastin could be strong solid-tumor fighter
|
11/15/2005 | BT | Oxigene announces positive phase 1b trial data for use of CA4P against ovarian cancer
|
11/10/2005 | BT | OxiGene vascular-disrupting drugs, anti-angiogenic agents may have synergies, oncology researcher says
|
9/23/2005 | BTCV | Oxigene files $75 million shelf
|
3/8/2005 | PP | Market Commentary: Private placements stall on lower stocks; Vistula closes $8.4 million offering
|
3/7/2005 | PP | Market Commentary: Canadian private placement issuance powered by oil; Producers prices C$80 million deal
|
3/4/2005 | PP | New Issue: Oxigene closes direct placement of stock for $15.01 million
|
3/4/2005 | PP | Market Commentary: Private placement volume gets boost from stocks; Oxigene closes $15 million deal
|